Nathan Jorgensen's most recent trade in Boise Cascade Co was a trade of 25,323 Common Stock, par value $0.01 done . Disclosure was reported to the exchange on March 1, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Boise Cascade Co | Nathan Jorgensen | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2025 | 25,323 | 269,542 (0%) | 0% | 0 | Common Stock, par value $0.01 | |
| Boise Cascade Co | Nathan Jorgensen | Director, CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 103.66 per share. | 01 Mar 2025 | 12,008 | 257,534 (0%) | 0% | 103.7 | 1,244,749 | Common Stock, par value $0.01 |
| Boise Cascade Co | Nathan Jorgensen | Director, CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 103.66 per share. | 01 Mar 2025 | 9,365 | 248,169 (0%) | 0% | 103.7 | 970,776 | Common Stock, par value $0.01 |
| Voyager Therapeutics Inc | Nathan Jorgensen | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Feb 2025 | 103,000 | 103,000 | - | - | Stock Option (Right to Buy) | |
| Voyager Therapeutics Inc | Nathan Jorgensen | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Feb 2025 | 51,500 | 131,500 (0%) | 0% | 0 | Common Stock | |
| Voyager Therapeutics Inc | Nathan Jorgensen | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Oct 2024 | 80,000 | 80,000 (0%) | 0% | 0 | Common Stock | |
| Voyager Therapeutics Inc | Nathan Jorgensen | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jul 2024 | 200,000 | 200,000 | - | - | Stock Option (Right to Buy) | |
| Vor Biopharma Inc | Nathan Jorgensen | CHIEF FINANCIAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.75 per share. | 06 May 2024 | 834 | 189,403 | - | 1.8 | 1,460 | Common Stock |
| Vor Biopharma Inc | Nathan Jorgensen | CHIEF FINANCIAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.77 per share. | 01 May 2024 | 917 | 190,237 | - | 1.8 | 1,623 | Common Stock |
| Boise Cascade Co | Nathan Jorgensen | Director, CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 137.79 per share. | 01 Mar 2024 | 19,067 | 254,054 (0%) | 0% | 137.8 | 2,627,242 | Common Stock, par value $0.01 |
| Boise Cascade Co | Nathan Jorgensen | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 18,144 | 273,121 (0%) | 0% | 0 | Common Stock, par value $0.01 | |
| Boise Cascade Co | Nathan Jorgensen | Director, CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 137.79 per share. | 01 Mar 2024 | 9,835 | 244,219 (0%) | 0% | 137.8 | 1,355,165 | Common Stock, par value $0.01 |
| Vor Biopharma Inc | Nathan Jorgensen | CHIEF FINANCIAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.27 per share. | 01 Mar 2024 | 6,310 | 191,154 | - | 2.3 | 14,324 | Common Stock |
| Boise Cascade Co | Nathan Jorgensen | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2024 | 53,368 | 254,977 (0%) | 0% | 0 | Common Stock, par value $0.01 | |
| Vor Biopharma Inc | Nathan Jorgensen | CHIEF FINANCIAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.32 per share. | 06 Feb 2024 | 985 | 197,464 | - | 2.3 | 2,285 | Common Stock |
| Vor Biopharma Inc | Nathan Jorgensen | CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jan 2024 | 100,000 | 100,000 | - | - | Employee Stock Option (right to buy) | |
| Vor Biopharma Inc | Jorgensen Nathan | CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jan 2024 | 50,000 | 198,449 | - | 0 | Common Stock | |
| Vor Biopharma Inc | Nathan Jorgensen | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.67 per share. | 07 Aug 2023 | 834 | 152,791 | - | 2.7 | 2,227 | Common Stock |
| Vor Biopharma Inc | Nathan Jorgensen | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.14 per share. | 08 May 2023 | 834 | 153,625 | - | 4.1 | 3,453 | Common Stock |
| Boise Cascade Co | Nathan Jorgensen | Director, CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 69.33 per share. | 01 Mar 2023 | 27,437 | 212,000 (0%) | 0% | 69.3 | 1,902,207 | Common Stock, par value $0.01 |
| Boise Cascade Co | Nathan Jorgensen | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2023 | 26,684 | 239,437 (0%) | 0% | 0 | Common Stock, par value $0.01 | |
| Boise Cascade Co | Nathan Jorgensen | Director, CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 69.33 per share. | 01 Mar 2023 | 10,391 | 201,609 (0%) | 0% | 69.3 | 720,408 | Common Stock, par value $0.01 |
| Vor Biopharma Inc | Nathan Jorgensen | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.51 per share. | 01 Mar 2023 | 6,310 | 154,459 | - | 5.5 | 34,768 | Common Stock |
| Boise Cascade Co | Nathan Jorgensen | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Feb 2023 | 26,656 | 212,753 (0%) | 0% | 0 | Common Stock, par value $0.01 | |
| Vor Biopharma Inc | Nathan Jorgensen | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Feb 2023 | 91,000 | 91,000 | - | - | Employee Stock Option (right to buy) | |
| Vor Biopharma Inc | Nathan Jorgensen | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Feb 2023 | 45,500 | 160,769 | - | 0 | Common Stock | |
| Vor Biopharma Inc | Nathan Jorgensen | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Sep 2022 | 86,000 | 86,000 | - | - | Employee Stock Option (right to buy) | |
| Vor Biopharma Inc | Nathan Jorgensen | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Sep 2022 | 86,000 | 115,269 | - | 0 | Common Stock | |
| Boise Cascade Co | Nathan Jorgensen | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2022 | 17,537 | 198,881 (0%) | 0% | 0 | Common Stock, par value $0.01 | |
| Boise Cascade Co | Nathan Jorgensen | Director, CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 79.83 per share. | 01 Mar 2022 | 9,168 | 186,097 (0%) | 0% | 79.8 | 731,881 | Common Stock, par value $0.01 |
| Boise Cascade Co | Nathan Jorgensen | Director, CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 79.83 per share. | 01 Mar 2022 | 3,616 | 195,265 (0%) | 0% | 79.8 | 288,665 | Common Stock, par value $0.01 |
| Boise Cascade Co | Nathan Jorgensen | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Feb 2022 | 42,230 | 181,344 (0%) | 0% | 0 | Common Stock, par value $0.01 | |
| Vor Biopharma Inc | Nathan Jorgensen | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2022 | 135,000 | 135,000 | - | - | Employee Stock Option (right to buy) | |
| Boise Cascade Co | Nathan Jorgensen | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2021 | 21,115 | 139,114 (0%) | 0% | 0 | Common Stock, par value $0.01 | |
| Boise Cascade Co | Nathan Jorgensen | Director, CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 52.45 per share. | 01 Mar 2021 | 6,534 | 117,999 (0%) | 0% | 52.4 | 342,708 | Common Stock, par value $0.01 |
| Boise Cascade Co | Nathan Jorgensen | Director, CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 52.45 per share. | 01 Mar 2021 | 1,613 | 124,533 (0%) | 0% | 52.5 | 84,602 | Common Stock, par value $0.01 |
| Boise Cascade Co | Nathan Jorgensen | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Feb 2021 | 60,768 | 126,146 (0%) | 0% | 0 | Common Stock, par value $0.01 | |
| Vor Biopharma Inc | Nathan Jorgensen | Chief Financial Officer | 09 Feb 2021 | 48,076 | 0 | - | - | Series B Preferred Stock | ||
| Vor Biopharma Inc | Nathan Jorgensen | Chief Financial Officer | 09 Feb 2021 | 3,534 | 29,269 | - | - | Common Stock |